Reata is developing a diverse portfolio of anti-cancer agents

Other Technologies

In addition to our AIMs and Protein Folding platforms, Reata’s technology portfolio includes intellectual property rights to four classes of small molecule anti-cancer agents, the most advanced of which is in Phase 2 clinical trials.

	Novel DNA Binding Agents that are members of the anthracycline class of cancer agents and have been engineered to cross the blood-brain barrier and circumvent mechanisms of drug resistance. The lead agent in this class, berubicin hydrochloride, previously known as RTA 744, is in Phase 2 development for brain cancer. An orally available molecule in this class (RTA 769) is in preclinical development. Click here to view a recent publication on these compounds.
	Novel microtubule stabilizers that are structurally distinct from the taxanes and epothilones, and that appears synergistic with these other agents. The lead molecule in this class (RTA 301) has consistently outperformed the standard of care in animal models of multiple types of cancers.
	Topoisomerase I inhibitors with unique properties. Agents in this class have recently been shown to down-regulate ribonucleotide reductase (RNR), a DNA synthesis and repair enzyme, and cdc7, a kinase involved in mutagenesis and cell cycle control. They have demonstrated considerable activity against gastrointestinal cancers.
	V-ATPase inhibitors. This target appears to play a central role in mechanisms of radiation resistance, drug resistance, invasion and metastasis. Reata is conducting preclinical development of several classes of molecules against this important new cancer target.